Literature DB >> 19003911

Serum and ascitic fluid bacterial DNA: a new independent prognostic factor in noninfected patients with cirrhosis.

Pedro Zapater1, Rubén Francés, José M González-Navajas, Maria A de la Hoz, Rocío Moreu, Sonia Pascual, David Monfort, Silvia Montoliu, Carmen Vila, Amparo Escudero, Xavier Torras, Isabel Cirera, Lucía Llanos, Carlos Guarner-Argente, José M Palazón, Fernando Carnicer, Pablo Bellot, Carlos Guarner, Ramón Planas, Ricard Solá, Miguel A Serra, Carlos Muñoz, Miguel Pérez-Mateo, José Such.   

Abstract

UNLABELLED: We tested the hypothesis that the presence of bacterial DNA (bactDNA) in ascitic fluid and serum is associated with decreased survival in patients with cirrhosis. In a prospective, multicenter study, we analyzed the clinical evolution of 156 patients with cirrhosis and ascites (first or recurrence) with lower than 250 polymorphonuclear cells (PMN)/muL, negative ascites bacteriological culture, and absence of other bacterial infections being admitted for evaluation of large-volume paracentesis, according to the presence of bactDNA at admission. Survival, causes of death, and successive hospital admissions were determined during a 12-month follow-up period. BactDNA was detected in 48 patients. The most prevalent identified bactDNA corresponded to Escherichia coli (n = 32/48 patients, 66.6%). Patients were followed for 12 months after inclusion and in this period 34 patients died: 16 of 108 (15%) bactDNA negative versus 18 of 48 (38%) bactDNA positive (P = 0.003). The most frequent cause of death was acute-on-chronic liver failure in both groups (7/16 and 9/18 in patients without or with bactDNA, respectively), although more prevalent in the first month of follow-up in patients with presence of bactDNA (0 versus 4/7). When considering patients with model for end-stage liver disease (MELD) score less than 15, mortality was significantly higher in those with presence of bactDNA. Spontaneous bacterial peritonitis developed similarly in patients with or without bactDNA at admission.
CONCLUSION: The presence of bactDNA in a patient with cirrhosis during an ascitic episode is an indicator of poor prognosis. This fact may be related to the development of acute-on-chronic liver failure at short term and does not predict the development of spontaneous bacterial peritonitis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19003911     DOI: 10.1002/hep.22564

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  51 in total

1.  Presence of multiple bacterial markers in clinical samples might be useful for presumptive diagnosis of infection in cirrhotic patients with culture-negative reports.

Authors:  M Boaretti; F Castellani; M Merli; C Lucidi; M M Lleo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-01-11       Impact factor: 3.267

2.  Application of qualitative and quantitative real-time PCR, direct sequencing, and terminal restriction fragment length polymorphism analysis for detection and identification of polymicrobial 16S rRNA genes in ascites.

Authors:  Sandra Krohn; Stephan Böhm; Cornelius Engelmann; Jan Hartmann; Annika Brodzinski; Antonis Chatzinotas; Katharina Zeller; Delia Prywerek; Ingo Fetzer; Thomas Berg
Journal:  J Clin Microbiol       Date:  2014-03-12       Impact factor: 5.948

Review 3.  The role of microbiota in hepatic encephalopathy.

Authors:  Jasmohan S Bajaj
Journal:  Gut Microbes       Date:  2014-04-01

Review 4.  Altered Microbiome in Patients With Cirrhosis and Complications.

Authors:  Chathur Acharya; Jasmohan S Bajaj
Journal:  Clin Gastroenterol Hepatol       Date:  2018-08-09       Impact factor: 11.382

Review 5.  Markers of bacterial translocation in end-stage liver disease.

Authors:  Ioannis Koutsounas; Garyfallia Kaltsa; Spyros I Siakavellas; Giorgos Bamias
Journal:  World J Hepatol       Date:  2015-09-18

Review 6.  Update on adrenal insufficiency in patients with liver cirrhosis.

Authors:  Anca Trifan; Stefan Chiriac; Carol Stanciu
Journal:  World J Gastroenterol       Date:  2013-01-28       Impact factor: 5.742

7.  Proteomic evidence of bacterial peptide translocation in afebrile patients with cirrhosis and ascites.

Authors:  Rocío Caño; Lucía Llanos; Pedro Zapater; Sonia Pascual; Pablo Bellot; Claudia Barquero; Miguel Pérez-Mateo; José Such; Rubén Francés
Journal:  J Mol Med (Berl)       Date:  2010-01-20       Impact factor: 4.599

8.  Presence of anti-microbial antibodies in liver cirrhosis--a tell-tale sign of compromised immunity?

Authors:  Maria Papp; Gary L Norman; Zsuzsanna Vitalis; Istvan Tornai; Istvan Altorjay; Ildiko Foldi; Miklos Udvardy; Zakera Shums; Tamas Dinya; Peter Orosz; Bela Lombay; Gabriella Par; Alajos Par; Gabor Veres; Timea Csak; Janos Osztovits; Ferenc Szalay; Peter Laszlo Lakatos
Journal:  PLoS One       Date:  2010-09-23       Impact factor: 3.240

9.  The interstitial lymphatic peritoneal mesothelium axis in portal hypertensive ascites: when in danger, go back to the sea.

Authors:  M A Aller; I Prieto; S Argudo; F de Vicente; L Santamaría; M P de Miguel; J L Arias; J Arias
Journal:  Int J Inflam       Date:  2010-10-05

Review 10.  New determinants of prognosis in bacterial infections in cirrhosis.

Authors:  Juan Acevedo; Javier Fernández
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.